Eastern Health, Melbourne, VIC, Australia.
Eastern Health, Melbourne, VIC, Australia; Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia.
Semin Oncol Nurs. 2020 Aug;36(4):151047. doi: 10.1016/j.soncn.2020.151047. Epub 2020 Jul 22.
Prostate cancer is one of the most common male cancers in the world and accounts for substantial morbidity, mortality, loss of disability-adjusted life-years, and financial burden to patients and to the community. Metastatic prostate cancer has been managed for over 70 years with androgen deprivation therapy, but further life-prolonging therapies were not available until 2004. Since then, drugs such as docetaxel, abiraterone, enzalutamide, cabazitaxel, radium-223 dichloride, and (not available in Australia) sipuleucel-T have all demonstrated efficacy in prolongation of survival in castrate-resistant prostate cancer, and improvement in cancer-related morbidity.
Peer-reviewed scientific publications, Australian Government agency reports, and expert opinion.
More recently, several of these agents have been given earlier in the treatment course to the hormone-sensitive metastatic setting, with even greater benefits in survival. These treatments have come at a cost: a literal financial cost to the community, and often to the patients and their families; and financial costs to the community to supply the drugs to those who need them. They also carry non-financial costs, including side effects of treatment, exacerbation of other co-morbidities, metabolic and bone health challenges, and psychological and social stresses, including those associated with longer survival with metastatic cancer.
The role of the nurse in management of these issues has never been more important. Nurses are often uniquely placed to educate men with prostate cancer and their families, screen for and identify adverse effects of treatment, and provide education and support not otherwise available. Nurses are central to the streamline of care coordination within the multidisciplinary team and the holistic care journey for men and their partners through the health care system. This review discusses several of these aspects to inform practice.
前列腺癌是全球最常见的男性癌症之一,给患者及其所在社区带来了巨大的发病率、死亡率、丧失经过残疾调整的生命年以及经济负担。转移性前列腺癌已经通过雄激素剥夺疗法进行了 70 多年的治疗,但直到 2004 年才出现进一步延长生命的疗法。从那时起,多西他赛、阿比特龙、恩扎鲁胺、卡巴他赛、镭-223 二氯化物和(澳大利亚不可用)sipuleucel-T 等药物都已被证明能延长去势抵抗性前列腺癌患者的生存时间,并改善癌症相关发病率。
同行评议的科学出版物、澳大利亚政府机构报告和专家意见。
最近,这些药物中的几种已更早地用于激素敏感的转移性疾病治疗,生存获益更大。这些治疗方法带来了成本:对社区的实际经济成本,通常对患者及其家属也是如此;为有需要的人提供药物也给社区带来了经济成本。它们还带来了非经济成本,包括治疗的副作用、其他合并症的恶化、代谢和骨骼健康挑战以及心理和社会压力,包括与转移性癌症更长生存时间相关的压力。
护士在管理这些问题方面的作用从未如此重要。护士通常处于独特的位置,能够对前列腺癌患者及其家属进行教育,筛查和识别治疗的不良反应,并提供其他方面无法提供的教育和支持。护士是多学科团队内的护理协调流程以及男性及其伴侣在整个医疗保健系统中的整体护理旅程的核心。这篇综述讨论了其中的几个方面,以指导实践。